GlassScriptPhysician profile
Anisha Sara Jacob
NPI 1891452959
$3,613.56
in general payments reported to CMS, 2019-2025
27 companies · $917 in 2025
The $917 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $629 · 2023: $635 · 2024: $1,433 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,984.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $742.39 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $550.45 | 2022-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $414.20 | 2023-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $262.74 | 2022-2025 | Xtampza, Belbuca |
| Tersera Therapeutics LLC | $239.88 | 2022-2025 | Prialt |
| Vertex Pharmaceuticals Incorporated | $214.50 | 2024-2025 | |
| Forte Bio-Pharma LLC | $148.04 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Idorsia Pharmaceuticals US INC | $119.23 | 2022-2024 | Quviviq |
| Valinor Pharma, LLC | $113.90 | 2023-2025 | Movantik |
| Pfizer INC. | $90.58 | 2023-2024 | |
| Indivior INC. | $72.73 | 2023-2025 | Sublocade |
| Averitas Pharma INC. | $67.80 | 2024-2025 | Qutenza |
| Orexo US, INC. | $63.30 | 2022-2025 | Zubsolv |
| Redhill Biopharma INC. | $60.31 | 2022 | |
| Djo, LLC | $58.80 | 2024 | Cmf |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $54.10 | 2022-2024 | Gelsyn-3 |
| Curonix LLC | $49.75 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Depuy Synthes Sales INC. | $48.68 | 2022-2023 | Orthovisc |
| Novo Nordisk INC | $42.34 | 2024-2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $39.99 | 2022 | |
| Protega Pharmaceutials INC | $35.76 | 2025 | Roxybond |
| Axsome Therapeutics, INC. | $24.93 | 2025 | Symbravo |
| Nevro Corp. | $23.77 | 2024 | Senza |
| Grt US Holding, INC. | $21.54 | 2022 | |
| Virtus Pharmaceuticals LLC | $18.89 | 2024 | Levorphanol Tartrate |
| Vertical Pharmaceuticals, LLC | $18.35 | 2023 | Dsuvia |
| Almatica Pharma LLC | $16.61 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anisha Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.